Patient-derived prostate cancer: From basic science to the clinic

Research output: Contribution to journalArticleOtherpeer-review

5 Citations (Scopus)


Systems that model cancer form the backbone of research discovery, and their accuracy and validity are a key determinant to ensure successful translation. In many tumour types, patient-derived specimens are an important model of choice for pre-clinical drug development. In this review, we consider why this has been such a challenge for prostate cancer, resulting in relatively few patient-derived xenografts (PDXs) of prostatic tumours compared to breast cancers, for example. Nevertheless, with only a few patient specimens and PDXs, we exemplify in three vignettes how important new clinical insights were obtained resulting in benefit for future men with prostate cancer.
Original languageEnglish
Pages (from-to)236-240
Number of pages5
JournalHormones and Cancer
Issue number4
Publication statusPublished - Aug 2016

Cite this